

TO: Members, Advisory Committee for Pharmaceutical Science

FROM: Helen Winkle  
Acting Director, Office of Pharmaceutical Science, CDER, FDA

Date: March 7, 2003

Re: Errata to Memo dated February 11, 2003 regarding ACPS Meeting March 12 and 13, 2003

In the section "Bioavailability / Bioequivalence of Endogenous Drugs", the last sentence should read as follows

"Abbott Laboratories will present an overview of research it conducted on baseline correction methods for levothyroxine sodium. Some of Abbott's research findings were recently adopted by FDA for bioequivalence testing on levothyroxine products. Abbott will also discuss other approaches for baseline correction."